Immunosaccharide Technologies Inc and Tufts University are attempting to improve already existing vaccines with an additive that improves the effectiveness of the drug. Dr. Panilaitis, a research associate in the Department of Biomedical Engineering at Tufts, intends to commercialize Emulsan-based Vaccine Adjuvants, which show promise for improving a Lyme disease vaccine, as well as other similar drugs.
